Objective: The NHS Bowel Cancer Screening Programme (BCSP) uses faecal occult blood (FOB) testing to select patients aged 60–69 years for colonoscopy. Aim: To examine the association between aspirin use and the detection of colorectal neoplasia in screened patients undergoing colonoscopy. Methods: Data were collected prospectively on individuals who underwent colonoscopy following a positive FOB test in the South of Tyne area between February 2007 and 2009. The relationship between the presence of colorectal neoplasia and age, gender, body mass index (BMI) and current aspirin use were evaluated using logistic regression analysis. Results: 701 individuals underwent colonoscopy. 414 (59.1%) were male and 358 (51.1%) aged over 65 years. Males had a higher incidence of colorectal neoplasia (relative risk 2.26, 95% CI 1.65–3.10, p < 0.001). Current aspirin use was associated with a lower neoplasia detection rate (relative risk 0.79, 95% CI 0.50–0.98, p = 0.039). Increased age and BMI were not significantly associated with higher neoplasia detection. Conclusion: Amongst individuals undergoing colonoscopy following a positive FOB test in the BCSP, current aspirin use was associated with a lower incidence of colorectal neoplasia. This may represent the chemopreventative effect of aspirin or increased false positivity of FOB testing. Further work is needed to clarify the contribution of each and could reduce the number of unnecessary colonoscopies.

1.
Cancer Research UK. Cancerstats. http://info.cancerresearchuk.org/cancerstats/types/bowel/incidence/ (accessed February 2010).
2.
Office for National Statistics, Cancer Statistics Registrations: Registrations of cancer diagnosed in 2006, England. 2009.
3.
http://www.cancerscreening.nhs.uk/bowel/index.html (accessed February 2010).
4.
Fearnhead NS, Wilding JL, Bodmer WF: Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 2002;64:27–43.
[PubMed]
5.
Kant P, Hull MA: Excess body weight and obesity – the link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol 2011;8:224–238.
6.
Anderson JC, Attam R, Alpern Z, Messina CR, Hubbard P, Grimson R, et al: Prevalence of colorectal neoplasia in smokers. Am J Gastroenterol 2003;98:2777–2783.
[PubMed]
7.
Martinez ME, MacPherson RS, Annegers JF, Levin B: Cigarette smoking and alcohol consumption as risk factors for colorectal adenomatous polyps. J Natl Cancer Inst 1995;87:274–279.
8.
Norat T, Bingham S, Ferrari P, Slimani N, Jenad M, Mazair M, et al: Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 2005;97:906–916.
[PubMed]
9.
World Cancer Research Fund/American Institute for Cancer Research: Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, AICR, 2007.
10.
Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ: Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011;106:1340-1350.
11.
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA: Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256–266.
[PubMed]
12.
Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, Meade TW: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741–1750.
[PubMed]
13.
Din FVN, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H, Dunlop MG: Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010;59:e1670–1679.
[PubMed]
14.
Clarke P, Jack F, Carey FA, Steele RJ: Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis 2006;8:389–392.
15.
Sawhney MS, McDougall H, Nelson DB, Bond JH: Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010;55:1637–1642.
16.
Greenberg PD, Cello JP, Rockey DC: Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc 1999;50:618–622.
17.
Alquhist DA, McGill DB, Schwarz S, et al: Faecal blood levels in health and disease. A study using HemoQuant. N Engl J Med 1985;312:1422–1428.
18.
Thomas WM, Hardcastle JD: Role of upper gastrointestinal investigations in a screening study for colorectal neoplasia. Gut 1990;31:1294–1297.
19.
Segnan N, Patnick J, von Karsa L (eds): European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, ed 1. Luxembourg, Publications Office of the European Union, 2011.
You do not currently have access to this content.